Aletti 2006.

Study characteristics
Methods	Retrospective cohort study of consecutive women identified from surgical records
Participants	Women with FIGO stage IIIC ovarian cancer, where disease status was extracted from surgical exploration notes The mean and median age at study entry was 64.4 and 64 years respectively (range: 24 to 87) All women presented with FIGO stage IIIC ‐ 194 (100%) Tumour cell type: serous 126 (64.9%), mucinous: 4 (2.1%), endometrioid: 18 (9.3%), clear cell: 7 (3.6%), mixed: 17 (8.8%), seroanaplastic: 17 (8.8%), mullerian origin: 2 (1%) Tumour grade: 1: 1 (0.5%), 2: 13 (6.7%), 3: 180 (92.8%) ASA score: 1: 7 (3.6%), 2: 87 (44.8%), 3: 88 (45.4%), 4: 7 (3.6%), unknown: 5 (2.6%) Ascites: mean: 2076 mL, median 1000 mL, (range: 0 to 12,000 mL) Extent of disease: carcinomatosis: 144 (74.2%), diaphragm involvement: 137 (70.6%), mesentery: 138 (71.1%), cul‐de‐sac: 163 (84%), omentum 168: (86.6%), ascites 160: (82.5%)
Residual disease details	Residual disease was noted as follows: NMRD: 46 (23.7%) SVRD: 85 (43.8%) Residual disease of 1 cm to 2 cm: 22 (11.3%) Residual disease larger than 2cm: 41 (21.1%) Optimal cytoreduction was defined as residual disease < 1 cm All women were scheduled for treatment with first‐line postoperative platinum‐based chemotherapy (paclitaxel or cyclophosphamide for 6 to 8 courses, every 3 to 4 weeks)
Outcomes	Overall survival, HR adjusted for several prognostic categories: SVRD vs NMRD: HR 3.89 (95% CI 2.27 to 7.11) 1 cm to 2 cm vs NMRD: HR 6.25 (95% CI 3.16 to 12.61) > 2 cm vs NMRD: HR 13.00 (95% CI 7.14 to 24.87) Adverse events: Perioperative mortality rate, defined as the percentage of women who died within 30 days of surgery, was 1.5% (3/194; 95% CI 0.5 to 4.4%). However, there was no breakdown by treatment arm.
Risk of bias (QUIPS)	1. Study participation (a‐f): low risk Adequate number of participants and description of target population. Baseline characteristics, eligibility criteria, sampling frame and period/place study took place presented clearly. 2. Study attrition (a‐e): unclear risk Unclear if patients with incomplete follow‐up were excluded before arriving at the stated sample size. Insufficient information to permit judgement. 3. Prognostic factor measurement (a‐f): low risk Valid and reliable measurement of RD Outcome level assessment: Outcome: overall survival 4. Outcome measurement (a‐c): high risk Overall survival not used as outcome. Rather, disease‐specific survival was used. 5. Adjustment for other prognostic factors (a‐g): low risk HR for disease‐specific survival was adjusted for residual disease, age, American Society of Anesthesiology (ASA) score, histological grade, operative time and aggressive surgery in multivariable Cox model 6. Statistical analysis and reporting (a‐d): unclear risk In methods, authors reported that significant variables from the univariate analysis were included in the multivariable model Outcome: progression‐free survival Not reported
Notes	Median length of follow‐up: 2.7 years Mean length of follow‐up: 3.5 years (range 0.02 to 10.5 years) 5‐year disease‐specific death rate: Optimal group: 70/131 (53.4%) Suboptimal group: 56/63 (88.9%)